Fractyl Health survey finds 33% of GLP-1 users prefer one-time procedure
GUTS•Fractyl Health said 33% of nearly 300 surveyed GLP-1 users preferred a one-time procedure over continued medication.
1. Survey and trial plans
Fractyl Health said the survey supports commercialization planning for its investigational Revita procedure. The company cited an estimated one million U.S. patients discontinuing GLP-1 medications monthly; 12-month pivotal trial results are expected in the first quarter of 2027.
